Allergan Leadership

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>AP</div>
AGN -- USA Stock  

Earnings Report: 4th of August 2020  

Allergan Plc employes about 17.4 K people. The company is managed by 35 executives with total tenure of roughly 157 years, averaging almost 4.0 years of service per executive having 497.14 employees per reported executive. Inspection of Allergan Plc management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Allergan Plc future performance. Please continue to Trending Equities.

Search Insiders

 
Refresh
  Brenton Saunders  Chairman
Chairman of the Board, President, Chief Executive Officer
  Paul Bisaro  Chairman
Executive Chairman
  Matthew Walsh  President
Chief Financial Officer, Executive Vice President

Allergan Plc Management Team Effectiveness

Allergan Plc has Return on Asset of (0.0564) % which means that on every $100 spent on asset, it lost $0.0564. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (0.0913) %, meaning that it generated no profit with money invested by stockholders. Allergan Plc management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities.

Allergan Plc Workforce Comparison

Allergan Plc is rated below average in number of employees category among related companies. The total workforce of Drug Manufacturers?General industry is presently estimated at about 177,380. Allergan Plc holds roughly 17,400 in number of employees claiming about 10% of equities under Drug Manufacturers?General industry.

Allergan Plc Insider Trading

Allergan Plc Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Allergan Plc Price Series Summation is a cross summation of Allergan Plc price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.

Allergan Plc Stakeholders

Brenton Saunders Chairman of the Board, President, Chief Executive Officer
Paul Bisaro Executive Chairman
Matthew Walsh Chief Financial Officer, Executive Vice President
Robert Stewart Executive VP and President of Generic and Global Operations
William Meury Executive Vice President, Chief Commercial Officer
Wayne Swanton Executive Vice President - Global Operations
Karen Ling Chief Human Resource Officer, Executive Vice President
Philippe Schaison Executive Vice President and President Allergan Medical
A Bailey Executive Vice President, Chief Legal Officer and Corporate Secretary
CDavid Nicholson Executive Vice President, Chief R&D Officer
Jonathon Kellerman Executive Vice President Chief Compliance Officer
Paul Navarre Executive Vice President and President International Brands
Maria Hilado CFO and Executive VP
Ronald Taylor Independent Director
Adriane Brown Independent Director
Robert Hugin Independent Director
Christopher Bodine Independent Director
Michael Gallagher Lead Independent Director
Thomas Freyman Independent Director
Catherine Klema Lead Independent Director
Christopher Coughlin Lead Independent Director
Nesli Basgoz Independent Director
Joseph Boccuzi Independent Director
Patrick OSullivan Independent Director
Fred Weiss Independent Director
Carol Davidson Independent Director
Michael Greenberg Independent Director
Ron Taylor Independent Director
James Bloem Independent Director
Peter McDonnell Independent Director
Robert Bailey Chief Legal Officer and Corporate Secretary
Nicholson Chief R&D Officer
James DArecca Chief Accounting Officer
Alex Kelly Chief Communications Officer
Karina Calzadilla IR Contact Officer

About Allergan Plc Management Performance

The success or failure of an entity such as Allergan Plc often depends on how effective the management is. Allergan Plc management team is responsible for propelling the future growth in the right direction and for administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Allergan management before purchasing its stock. It's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Allergan management is utilizing all available resources in the best possible way? Also, how well is the company doing, relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity. Please read more on our stock advisor page.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. As of May 8, 2020, Allergan plc operates as a subsidiary of AbbVie Inc. Allergan Plc operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange. It employs 17400 people.

Allergan Plc Manpower Efficiency

Return on Allergan Plc Manpower

Revenue Per Employee909.2 K
Revenue Per Executive452 M
Net Loss Per Employee531.6 K
Net Loss Per Executive264.3 M
Working Capital Per Employee16.5 K
Working Capital Per Executive8.2 M
Please continue to Trending Equities. Please also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page